Clinical Scorecard: Exploring the Use of Losartan in Treating Fibrostenosing Crohn’s Disease: A Strong Preclinical Justification

At a Glance

Key Highlights

• Losartan, an angiotensin receptor blocker (ARB), suppresses pro-fibrotic mediators and fibroblast activation in vitro.
• In a CD-like ileitis mouse model, losartan reduces inflammation, fibrosis severity, and prevents fibrosis relapse post-steroid remission.
• Retrospective clinical data suggest ACE inhibitors and ARBs may reduce IBD flares, hospitalizations, and surgeries, supporting RAS targeting.

Guideline-Based Recommendations

Diagnosis

• Assessment of intestinal fibrosis in Crohn’s disease remains challenging due to lack of standardized scoring systems.

Management

• Consider RAS pathway inhibition with losartan as a potential adjunctive therapy to reduce intestinal fibrosis and inflammation in fibrostenosing Crohn’s disease.
• Continue standard anti-inflammatory treatments; losartan may prevent fibrosis relapse after steroid-induced remission.

Monitoring & Follow-up

• Monitor intestinal inflammation and fibrosis progression clinically and via imaging where available.
• Observe for changes in disease activity and fibrosis severity during losartan therapy in clinical trials.

Risks

• Current evidence is preclinical; clinical safety and efficacy of losartan in Crohn’s disease require validation in controlled trials.
• Potential confounding factors in observational studies necessitate cautious interpretation of retrospective data.

Patient & Prescribing Data

Patients with Crohn’s disease exhibiting fibrostenosing complications

Preclinical models show losartan reduces fibrosis and inflammation; retrospective studies associate ARB use with milder disease course and fewer hospitalizations, but prospective clinical data are lacking.

Clinical Best Practices

• Integrate RAS pathway evaluation in research protocols for fibrostenosing Crohn’s disease.
• Use losartan as an adjunct only within clinical trials until efficacy and safety are established.
• Continue monitoring established anti-inflammatory and immunomodulatory therapies alongside any RAS-targeting agents.
• Recognize the need for standardized fibrosis scoring to improve diagnosis and treatment assessment.

References

• Artone et al. study on losartan in Crohn’s disease-like ileitis
• Garg et al. on ACE inhibitors/ARBs in IBD outcomes
• Mantaka et al. linking Ang II to IBD pathogenesis
• Wengrower et al. on ACE inhibitors preventing colonic fibrosis
• Study on ACE2 expression and anti-cytokine therapy in IBD